Drug Type Gene therapy |
Synonyms LGMD-R3/LGMD2D program, LGMD-R3/LGMD2D program (Atamyo), LGMD2D therapy(Atamyo Therapeutics) |
Target |
Action stimulants |
Mechanism SGCA stimulants(Alpha-sarcoglycan stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sarcoglycanopathies | Preclinical | France | 09 Aug 2022 |